Subscribe To

Price Alert Latest News Economic Calendar News

BBIO / BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study

BridgeBio Pharma smashed Wall Street's expectations in a study of children with dwarfism, leading BBIO stock to break out in massive volume. The post BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study appeared first on Investor's Business Daily. Read More

Demo Live Account See Partner Details

Content Topics

Bridgebio

Soars

Breaks

After

Smashing

Expectations

Dwarfism

Stock

BBIO

Posted: Mar 6 2023, 09:24

Author Name: Investors Business Daily

BBIO News

By The Motley Fool
October 24, 2023

Why BridgeBio Pharma Was a Healthy Stock Today

A well-respected financial services company initiated coverage on the biotech. It flagged it with its equivalent of a buy recommendation.

By Seeking Alpha
September 25, 2023

BridgeBio: Bets Acoramidis As The Pfizer Spoiler

BridgeBio Pharma's Q2 2023 YoY revenue plummeted, but PIPE financing extends cash runway to 15 months, alleviating short-term liquidity concerns. Acor

By GuruFocus
September 1, 2023

Andreas Halvorsen's Firm Ups Inhibrx Stake

Viking Global Investors, the investment firm founded by Andreas Halvorsen (Trades, Portfolio) in 1999, disclosed earlier this week it boosted its stak

By GlobeNewsWire
August 24, 2023

BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023

PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage

By The Motley Fool
August 9, 2023

Wall Street Thinks BridgeBio Pharma Could Rise Over 40% -- But Will It?

This young biotech might soon commercialize a new medicine. Analysts see BridgeBio's shares headed upward.

By The Motley Fool
July 21, 2023

Why Shares of BridgeBio Pharma Skyrocketed This Week

BridgeBio Pharma focuses on oncology and genetic diseases. The company said that acoramidis fared well in treating a heart muscle disease.

By GuruFocus
July 18, 2023

BridgeBio Pharma Surges on Positive Heart Drug News

BridgeBio Pharma ( BBIO , Financial) is a clinical-stage biopharmaceutical company that focuses on developing transformative medicines for patients wi

By Zacks Investment Research
July 18, 2023

BridgeBio Pharma (BBIO) Moves 75.9% Higher: Will This Strength Last?

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.